Rucaparib for Non-Small Cell Lung Cancer
Trial Summary
What is the purpose of this trial?
This phase II Lung-MAP trial studies how well rucaparib works in treating patients with genomic loss of heterozygosity (LOH) high and/or deleterious BRCA1/2 mutation stage IV non-small cell lung cancer or that has come back. Rucaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Research Team
Jonathan W Riess
Principal Investigator
SWOG Cancer Research Network
Eligibility Criteria
This trial is for adults with stage IV or recurrent non-small cell lung cancer that have high genomic loss of heterozygosity (LOH) or harmful BRCA1/2 mutations. Participants must be able to take oral medications, not have certain liver conditions, infections, or recent major surgeries. They should not have had prior treatment with PARP inhibitors and must agree to use effective contraception if of reproductive potential.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive rucaparib orally twice daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Follow-up
Participants are monitored for safety and effectiveness after treatment completion, with follow-ups every 3 months for 1 year, then every 6 months for up to 3 years.
Treatment Details
Interventions
- Rucaparib
Find a Clinic Near You
Who Is Running the Clinical Trial?
SWOG Cancer Research Network
Lead Sponsor
Southwest Oncology Group
Lead Sponsor
National Cancer Institute (NCI)
Collaborator